ImpediMed (ASX:IPD) has signalled a sharper focus on sales execution and market expansion following a strong finish to the financial year 2025, underpinned by record contract value, growing reimbursement coverage in the US, and advancing opportunities in lymphoedema, body composition and heart failure. …
ImpediMed accelerates growth strategy on strong results and expanding market reach
October 23, 2025 Australian Biotech
Latest Video
New Stories
-
Island Pharmaceuticals secures FDA response date for Galidesivir approval pathway
October 23, 2025 - - Australian Biotech -
Noxopharm granted first US patent for Sofra immune-modulation platform
October 23, 2025 - - Australian Biotech -
4DMedical secures Stanford as first commercial site and expands AstraZeneca partnership in Brazil
October 23, 2025 - - Australian Biotech -
ImpediMed accelerates growth strategy on strong results and expanding market reach
October 23, 2025 - - Australian Biotech -
Clarity Pharmaceuticals’ copper theranostics platform delivers superior prostate cancer imaging results
October 23, 2025 - - Australian Biotech -
Starpharma receives upfront payment from Genentech, launching oncology collaboration
October 23, 2025 - - Australian Biotech -
PYC Therapeutics launches global repeat-dose trial for potential first-in-class ADOA treatment
October 23, 2025 - - Australian Biotech